Travere Therapeutics, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
TVTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3611 Valley Centre Dr, Suite 300, San Diego, California

Insiders trading volume in the past year

Travere Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Eric M. Dube CHIEF EXECUTIVE OFFICER, Director $4.17M -$480K -10.3% Sep 5, 2024
Steve Aselage Director $1.32M May 11, 2022
Peter Heerma Chief Commercial Officer $1.24M -$101K -7.49% Sep 5, 2024
William E. Rote Senior Vice President, R&D $973K -$111K -10.2% Sep 5, 2024
Elizabeth E. Reed Svp, Gc & Corporate Secretary $906K -$111K -10.9% Sep 5, 2024
Christopher R. Cline Chief Financial Officer $859K -$74.2K -7.95% Sep 5, 2024
Jula Inrig Chief Medical Officer $804K -$76.3K -8.67% Sep 10, 2024
Jeffrey Meckler Director $546K May 8, 2024
Sandra Calvin Svp, Chief Accounting Officer $444K -$32.3K -6.79% Jan 31, 2024
Noah L. Rosenberg Chief Medical Officer $427K Aug 13, 2021
Gary A. Lyons Director $344K May 8, 2024
Timothy Coughlin Director $330K May 8, 2024
Laura Clague Chief Financial Officer $319K May 10, 2022
Roy D. Baynes Director $209K May 8, 2024
John A. Orwin Director $195K May 8, 2024
Ron Squarer Director $195K May 8, 2024
Sandra Poole Director $158K May 8, 2024
Suzanne Louise Bruhn Director $150K May 8, 2024
Brinkley Ruth Williams Director $130K May 8, 2024

Recent Insider Transactions by Companies or Individuals for Travere Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.